These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23610100)

  • 21. Effect of Dietary Phosphate Restriction in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphataemia in Southern Nigeria.
    Edeki IR; Unuigbe EI; Okaka EI
    West Afr J Med; 2024 Jun; 41(6):630-637. PubMed ID: 39340208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
    Yokoyama K; Hirakata H; Akiba T; Sawada K; Kumagai Y
    Am J Nephrol; 2012; 36(5):478-87. PubMed ID: 23147696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
    Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL
    BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease.
    Ahlenstiel T; Pape L; Ehrich JH; Kuhlmann MK
    Nephrol Dial Transplant; 2010 Oct; 25(10):3241-9. PubMed ID: 20308040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
    McIntyre CW; Pai P; Warwick G; Wilkie M; Toft AJ; Hutchison AJ
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):401-9. PubMed ID: 19158369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
    Cheng SC; Young DO; Huang Y; Delmez JA; Coyne DW
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1131-8. PubMed ID: 18385391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.
    Block GA; Persky MS; Shamblin BM; Baltazar MF; Singh B; Sharma A; Pergola P; Smits G; Comelli MC
    Nephron Clin Pract; 2013; 123(1-2):93-101. PubMed ID: 23797006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Rev Endocrinol Metab; 2015 Mar; 10(2):131-142. PubMed ID: 30293511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.
    Locatelli F; Del Vecchio L
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):489-99. PubMed ID: 25804298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.